Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P33681

UPID:
CD80_HUMAN

ALTERNATIVE NAMES:
Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1

ALTERNATIVE UPACC:
P33681; Q5DTA9; Q5DTB0

BACKGROUND:
T-lymphocyte activation antigen CD80, with alternative names such as Activation B7-1 antigen, BB1, and CTLA-4 counter-receptor B7.1, is integral to the costimulatory signal essential for T-lymphocyte activation. This protein's binding dynamics with CD28 and CTLA-4 dictate T-cell proliferation and cytokine production, underscoring its critical role in immune system modulation. Furthermore, its function as a receptor for adenovirus subgroup B implicates it in the body's defense against microbial infections.

THERAPEUTIC SIGNIFICANCE:
The exploration of T-lymphocyte activation antigen CD80's functions illuminates its potential in therapeutic applications. By targeting the mechanisms through which CD80 regulates T-cell activation and its interaction with pathogens, novel approaches for treating immune-related disorders and improving vaccine responses may be realized, marking a significant stride in medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.